Eli Lilly meets primary endpoint in LIBRETTO-431 study for NSCLC

Eli Lilly has met the primary endpoint in the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed with or without Keytruda.

LIBRETTO-431 (NCT04194944) is a Phase III, randomised, open-label trial evaluating Retevmo (selpercatinib) versus platinum-based chemotherapy, using cisplatin or carboplatin, and pemetrexed with or without Keytruda (pembrolizumab) in patients with non-small cell lung cancer (NSCLC).